Cargando…
Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease
INTRODUCTION: Low-dose computed tomography (LDCT) is used for screening for lung cancer (LC) in high-risk patients in the United States. The definition of high risk and the impact of frequent false-positive results of low-dose computed tomography remains a challenge. DNA methylation biomarkers are v...
Autores principales: | Weiss, Gunter, Schlegel, Anne, Kottwitz, Denise, König, Thomas, Tetzner, Reimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226366/ https://www.ncbi.nlm.nih.gov/pubmed/27544059 http://dx.doi.org/10.1016/j.jtho.2016.08.123 |
Ejemplares similares
-
Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients
por: Fleischhacker, Michael, et al.
Publicado: (2023) -
SHOX2 DNA Methylation is a Biomarker for the diagnosis of lung cancer based on bronchial aspirates
por: Schmidt, Bernd, et al.
Publicado: (2010) -
Control of carry-over contamination for PCR-based DNA methylation quantification using bisulfite treated DNA
por: Tetzner, Reimo, et al.
Publicado: (2007) -
A combined HM-PCR/SNuPE method for high sensitive detection of rare DNA methylation
por: Tierling, Sascha, et al.
Publicado: (2010) -
DNA Methylation Analysis of the SHOX2 and RASSF1A Panel Using Cell-Free DNA in the Diagnosis of Malignant Pleural Effusion
por: Zhang, Nana, et al.
Publicado: (2023)